利拉鲁肽治疗新发的1型糖尿病8例效果观察(2)
 |
| 第1页 |
参见附件。
[4] Degn KB.One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211)markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes[J]. Diabetes，2004，53：1187-1194.
[5] Creutzfeldt WO，Kleine N，Willms B，et al.Oucogontatic actions and reduction of fasting hyperglycemia by exogenous glucogon-like peptidel(7-36)amide in type 1 diabetic patients[J].Diabetes Care，1996，19：580-586.
[6] Behme MT，Dupre J，McDonald TJ，et al.Glucagun-like peptide limproved glycemic control in type l diabetes[J].BMC Endocr Disord，2003，10：1-9.
[7] Gutniak M，Orskov C， Hoist JJ，et al.Antidiabetogenie effect of Glucagon-like peptide-1(7-36)amide in normal subjects and patients with diabetes mellitus[J].N Engl J Med，1992，326：1316-1322.
[8] Ghofaili KA，Fung M，Ao Z，et al.Effect of exenatide on 8 eel function afar islet transplantation in type diabetes[J].Transplantation，2007，83：24-28.
(收稿日期：2013-03-18)
您现在查看是摘要介绍页，详见PDF附件。